These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39005045)

  • 1. Immunohistochemical expression of SATB2 and PAX8 in differentiating primary from metastatic ovarian mucinous neoplasms.
    El Ghondakly RA; El Haddad SI; AbdelSalam MM; Nada OH; Farid RM; Farid LM
    APMIS; 2024 Oct; 132(10):706-717. PubMed ID: 39005045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm.
    Aldaoud N; Erashdi M; AlKhatib S; Abdo N; Al-Mohtaseb A; Graboski-Bauer A
    BMC Res Notes; 2019 Nov; 12(1):770. PubMed ID: 31771640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
    Strickland S; Parra-Herran C
    Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
    Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
    Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of SATB2 immunohistochemical expression in colorectal cancer versus primary ovarian mucinous neoplasms.
    Maguire B; Duggan WP; Prehn JHM; Burke JP
    Ann Diagn Pathol; 2024 Aug; 71():152302. PubMed ID: 38642469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.
    Meagher NS; Wang L; Rambau PF; Intermaggio MP; Huntsman DG; Wilkens LR; El-Bahrawy MA; Ness RB; Odunsi K; Steed H; Herpel E; Anglesio MS; Zhang B; Lambie N; Swerdlow AJ; Lubiński J; Vierkant RA; Goode EL; Menon U; Toloczko-Grabarek A; Oszurek O; Bilic S; Talhouk A; García-Closas M; Wang Q; Tan A; Farrell R; Kennedy CJ; Jimenez-Linan M; Sundfeldt K; Etter JL; Menkiszak J; Goodman MT; Klonowski P; Leung Y; Winham SJ; Moysich KB; Behrens S; Kluz T; Edwards RP; Gronwald J; Modugno F; Hernandez BY; Chow C; Kelemen LE; Keeney GL; Carney ME; Natanzon Y; Robertson G; Sharma R; Gayther SA; Alsop J; Luk H; Karpinskyj C; Campbell I; Sinn P; Gentry-Maharaj A; Coulson P; Chang-Claude J; Shah M; Widschwendter M; Tang K; Schoemaker MJ; Koziak JM; Cook LS; Brenton JD; Daley F; Kristjansdottir B; Mateoiu C; Larson MC; Harnett PR; Jung A; deFazio A; Gorringe KL; Pharoah PDP; Minoo P; Stewart C; Bathe OF; Gui X; Cohen P; Ramus SJ; Köbel M
    Mod Pathol; 2019 Dec; 32(12):1834-1846. PubMed ID: 31239549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): A series of seven cases.
    Schmoeckel E; Kirchner T; Mayr D
    Pathol Res Pract; 2018 Mar; 214(3):426-430. PubMed ID: 29487003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.
    Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L
    Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
    Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
    Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours.
    Wang F; Yang Y; Du X; Zhu X; Hu Y; Lu C; Sui L; Zhao H; Song K; Yao Q
    BMC Cancer; 2023 Jan; 23(1):44. PubMed ID: 36639622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of SATB2 expression in colon cancer and its differential diagnosis in digestive tract adenocarcinoma and ovarian primary and metastatic carcinoma.
    Liu F; Gao Z; Shen D; Zhao H; Wang C; Ye Y; Ma Y; Kong F
    Pathol Res Pract; 2019 Jul; 215(7):152430. PubMed ID: 31101576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusely Metastasized Adenocarcinoma Arising in a Mucinous Carcinoid of the Ovary: A Case Report.
    Van Rompuy AS; Vanderstichele A; Vergote I; Moerman P
    Int J Gynecol Pathol; 2018 May; 37(3):290-295. PubMed ID: 28463910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality.
    Hu A; Li H; Zhang L; Ren C; Wang Y; Liu Y; Liu C
    J Clin Pathol; 2015 Jul; 68(7):522-8. PubMed ID: 25827135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
    Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J
    Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
    Ates Ozdemir D; Usubutun A
    Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Immunostain With SATB2 and CK20 Differentiates Appendiceal Mucinous Neoplasms From Ovarian Mucinous Neoplasms.
    Li Z; Roth R; Rock JB; Lehman A; Marsh WL; Suarez A; Frankel WL
    Am J Clin Pathol; 2017 May; 147(5):484-491. PubMed ID: 28340228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors.
    Chiesa-Vottero A
    Int J Gynecol Pathol; 2020 Mar; 39(2):170-177. PubMed ID: 32045390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma.
    Bassiouny D; Ismiil N; Dubé V; Han G; Cesari M; Lu FI; Slodkowska E; Parra-Herran C; Chiu HF; Naeim M; Li N; Khalifa M; Nofech-Mozes S
    Int J Surg Pathol; 2018 Jun; 26(4):306-317. PubMed ID: 29338553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of immunohistochemical markers, MUC1, MUC5AC, PAX8 and growth pattern for characterization of mucinous neoplasm of the ovary.
    Chelariu-Raicu A; Holley E; Mayr D; Klauschen F; Wehweck F; Rottmann M; Kessler M; Kaltofen T; Czogalla B; Trillsch F; Mahner S; Schmoeckel E
    Int J Gynecol Cancer; 2022 May; 32(5):662-668. PubMed ID: 35185017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas.
    Ji H; Isacson C; Seidman JD; Kurman RJ; Ronnett BM
    Int J Gynecol Pathol; 2002 Oct; 21(4):391-400. PubMed ID: 12352188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.